Story perspectives

Bayer Asks Judge to Approve $7.25B Roundup Settlement

By Drooid · Sep 15, 2026, 12:33 AM UTC · How we work

Summary

Monsanto Seeks Settlement

Bayer's Monsanto unit asked Judge Timothy Boyer to approve a $7.25 billion Roundup settlement.
The deal would resolve roughly 65,000 U.S. lawsuits alleging Roundup caused cancer.
Payouts under the proposal range from $10,000 to $165,000 for non-Hodgkin lymphoma victims.
Plaintiffs’ lawyer T. Roe Frazer said the $165,000 maximum is inadequate for many claimants.

Summary

Bayer Gains Momentum

Bayer received FDA accelerated approval for sevabertinib (HYRNUO) to treat HER2-mutated NSCLC on September 9, 2026.
Deutsche Bank Research kept a buy rating on Bayer with a EUR 60 price target on September 10, 2026.
Barclays upgraded Bayer to overweight and raised its price target to EUR 70 on September 8, 2026.
Bayer shares rose 2.5-3.9% on September 14, 2026, trading between EUR 49.36 and EUR 49.79.
Analysts’ consensus price target of EUR 58.22 suggests double-digit upside from Bayer’s high-40-euro range.

History

Historical Context

After the 1998 Master Settlement Agreement forced tobacco firms such as Philip Morris and R.J. Reynolds to pay $206 billion to 46 states, the deal set a benchmark for massive product-liability settlements. Bayer now faces Judge Timothy Boyer’s oversight of a proposed $7.25 billion payout to roughly 65,000 Roundup plaintiffs, echoing the tobacco case’s impact on corporate risk management.

1 of 3

Monsanto Seeks Settlement

Bayer's Monsanto unit asked Judge Timothy Boyer to approve a $7.25 billion Roundup settlement.
The deal would resolve roughly 65,000 U.S. lawsuits alleging Roundup caused cancer.
Payouts under the proposal range from $10,000 to $165,000 for non-Hodgkin lymphoma victims.
Plaintiffs’ lawyer T. Roe Frazer said the $165,000 maximum is inadequate for many claimants.

1 / 3